Sansure Biotech Inc Cash Flow Conversion Efficiency
Sansure Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Sansure Biotech Inc (688289) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.72 Million ≈ $8.74 Million USD) by net assets (CN¥7.22 Billion ≈ $1.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sansure Biotech Inc (2017–2025)
Cash flow conversion efficiency of Sansure Biotech Inc from 2017 to 2025. This chart illustrates how Sansure Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Sansure Biotech Inc stock price today for real-time trading data and today's change.
Sansure Biotech Inc Cash Flow Conversion Ratio Explained
Sansure Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sansure Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sansure Biotech Inc ranked by their cash flow conversion efficiency. Also see 688289 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dorchester Minerals LP
NASDAQ:DMLP
|
0.112x |
|
Zhongman Petro & Natural Gas
SHG:603619
|
0.126x |
|
Nations Technologies Inc
SHE:300077
|
-0.129x |
|
Qisda Corp
TW:2352
|
-0.072x |
|
Sociedad Matriz SAAM SA
SN:SMSAAM
|
-0.031x |
|
Arlo Technologies
NYSE:ARLO
|
0.072x |
|
Polestar Automotive Holding UK PLC Class A ADS
NASDAQ:PSNY
|
0.090x |
|
Accelevation Holdings Corp. Class A Ordinary Shares
NASDAQ:ACCV
|
-0.420x |
Annual Cash Flow Conversion Efficiency for Sansure Biotech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sansure Biotech Inc from 2017 to 2025. Review 688289 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.75 Billion ≈ $2.45 Billion |
CN¥183.96 Million ≈ $26.92 Million |
0.011x | -70.60% |
| 2024-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
CN¥274.45 Million ≈ $40.16 Million |
0.037x | +145.88% |
| 2023-12-31 | CN¥7.42 Billion ≈ $1.09 Billion |
CN¥112.82 Million ≈ $16.51 Million |
0.015x | -95.54% |
| 2022-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
CN¥2.56 Billion ≈ $374.45 Million |
0.341x | +15.80% |
| 2021-12-31 | CN¥6.38 Billion ≈ $933.79 Million |
CN¥1.88 Billion ≈ $274.67 Million |
0.294x | -47.17% |
| 2020-12-31 | CN¥4.75 Billion ≈ $694.40 Million |
CN¥2.64 Billion ≈ $386.65 Million |
0.557x | +1285.39% |
| 2019-12-31 | CN¥557.48 Million ≈ $81.58 Million |
CN¥22.41 Million ≈ $3.28 Million |
0.040x | +58.21% |
| 2018-12-31 | CN¥396.29 Million ≈ $57.99 Million |
CN¥10.07 Million ≈ $1.47 Million |
0.025x | +115.67% |
| 2017-12-31 | CN¥378.99 Million ≈ $55.46 Million |
CN¥-61.44 Million ≈ $-8.99 Million |
-0.162x | -- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more